http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012120546-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d6868a5151e6bd9ff0ecc9943c31b459 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a698cccb186f789799fa318a44ac7b97 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f0626ac3cfee44c85e365f1200f4563b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6a9ed66aaa70261433ad751378c2f549 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86 |
| filingDate | 2012-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9962907238a2fa779cf0de8dd1f0770 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_458ef3f455ab3b3fd28324e689661774 |
| publicationDate | 2012-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2012120546-A2 |
| titleOfInvention | Method for monitoring anticoagulant therapy |
| abstract | A method of measuring the combined activity of both and only coagulation factors II and X for the purpose of monitoring anticoagulant therapy, and kits for using the method. This is based on the hypothesis that the combined activity of factor II and factor X (FII and FX) more accurately reflects clottability and the antithrombotic effect of VKA anticoagulants in patients than conventional methods (eg PT, P&P). The method involves mixing of test plasma from a human to be tested with specially prepared plasma deficient in both and only coagulation factors II and X but with normal levels of other factors (referred to herein as Fiix-deficient plasma pr Fiix plasma), in order to correct for any possible deficiency in other coagulation factors than FII and FX in the test sample. By adding a coagulation reagent and calcium, the generation of thrombin or fibrin can be measured. Kits of the invention comprise a coagulation reagent, calcium and specially made plasma that is deficient in both and only factor II and factor FX. The kit components are suitably lyophilised. |
| priorityDate | 2011-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 123.